锦波生物(832982) - 2024 Q2 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 29,000 and 31,000 thousand yuan, representing an increase of 165.00% to 183.28% compared to the same period last year, which was 10,943.20 thousand yuan[4]. Investment and Growth Strategy - The company has increased its investment in research and development, as well as brand promotion and market expansion, leading to sustainable revenue growth[5]. Reporting and Auditing - The financial data provided is preliminary and has not been audited by an accounting firm, and the specific figures will be disclosed in the company's 2024 semi-annual report[6].